Online Only Articles

The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse

Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg, Germany;Molecular Medicine Partnership Unit, EMBL-University of Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg, Germany;Molecular Medicine Partnership Unit, EMBL-University of Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg, Germany;Molecular Medicine Partnership Unit, EMBL-University of Heidelberg, Germany
European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany
European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany
Childhood Leukemia Research Institute and Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, and Tel Aviv University, Israel
Childhood Leukemia Research Institute and Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, and Tel Aviv University, Israel;Division of Biological Sciences and Department of Medicine Stem Cell Program, University of California, San Diego, La Jolla, CA, USA
Childhood Leukemia Research Institute and Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, and Tel Aviv University, Israel
Childhood Leukemia Research Institute and Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, and Tel Aviv University, Israel
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg, Germany;Molecular Medicine Partnership Unit, EMBL-University of Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg, Germany;Molecular Medicine Partnership Unit, EMBL-University of Heidelberg, Germany
Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Germany
Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Germany;German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Pediatric Oncology/Hematology, Charité - Universitätsmedizin Berlin, Germany
Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Germany
Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Germany;Department of Pediatric Hematology/Oncology, Medical School Hannover, Germany
Department of Pediatric Hematology/Oncology, Medical School Hannover, Germany
Department of Human Genetics, University of Heidelberg, Germany
Molecular Oncology, Felsenstein Medical Research Center and Pediatric Hematology Oncology, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel
Children’s Hospital, University Hospital Tübingen, Germany
Department of Oncology, University Children’s Hospital Zurich, Switzerland
Department of Oncology, University Children’s Hospital Zurich, Switzerland
Department of Oncology, University Children’s Hospital Zurich, Switzerland
European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg, Germany;Molecular Medicine Partnership Unit, EMBL-University of Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg, Germany;Molecular Medicine Partnership Unit, EMBL-University of Heidelberg, Germany
Vol. 99 No. 10 (2014): October, 2014 https://doi.org/10.3324/haematol.2014.104992